Times Square Capital Management, LLC Mirati Therapeutics, Inc. Transaction History

Times Square Capital Management, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2019 Aug 02, 2019	SELL	$59.49 - $104.71 $14.4 Million - $25.3 Million	-241,300 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$43.65 - $78.95 $10.5 Million - $19.1 Million	241,300 New	241,300 $17.7 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Times Square Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Times Square Capital Management, LLC with notifications on news.